Physician profile
Jay D Davis
NPI 1225702889
$2,172.25
in general payments reported to CMS, 2019-2025
13 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $584 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.25 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.77 | 2024-2025 | |
| Amgen INC. | $604.13 | 2024-2025 | Krystexxa, Evenity, Prolia |
| Glaxosmithkline, LLC. | $317.37 | 2024-2025 | Benlysta |
| Ucb, INC. | $195.18 | 2024-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $119.79 | 2024-2025 | Saphnelo |
| Janssen Biotech, INC. | $107.89 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $32.71 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.51 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $22.82 | 2024 | Arcalyst |
| Boston Scientific Corporation | $22.72 | 2025 | Intracept |
| Alvogen INC | $22.49 | 2025 | Teriparatide |
| Pfizer INC. | $19.46 | 2025 | |
| Sobi, INC | $16.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.